查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1179953

2023-2030 年全球 DNA 检测市场

Global DNA Testing Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

在预测期内 (2023-2030)，全球 DNA 检测市场规模预计将以 7.4% 的复合年增长率增长。

DNA 测试，通常称为基因测试，是一种医学测试，可以检测人类基因、染色体或蛋白质的变化。 这些突变可以揭示一个人是否患有遗传病。 DNA 测试还可以确定您感染某些疾病或遗传遗传问题的风险。 DNA 测试是可选的。 是否接受测试是一个复杂的个人问题，因为测试有其优点、缺点和风险。 遗传学家或遗传咨询师可以通过概述测试的优缺点并检查其社会和情感影响来提供帮助。

市场动态

推动全球 DNA 检测市场发展的主要因素是新检测方法的开发和技术突破、直接面向消费者的 DNA 检测需求不断增长以及遗传病和慢性病发病率的增加。这是主要因素推动全球测试市场。

新测试的开发和技术突破有望推动市场增长。

如今，加速的技术发展为市场增长开闢了广泛的机会。 它正在推动专业治疗领域检测试剂盒市场的增长和慢性病市场的快速扩张。 一些国家的政府通过更加重视基因检测的监管和提高公众意识，成功地加速了全球对基因检测的接受。 不断增加的研发资金和主要参与者的大量市场占有率为新进入者创造了很高的进入壁垒。 产品设计创新、改进的质量标准和强大的分销合作伙伴关係是保持市场竞争力所必需的。

例如，2022年7月，Apollo高度专业化的高性能NGS检测，如遗传性癌症基因筛查（GCC）和药物遗传学筛查（PGx），将被引入到更广泛的临床领域将其推向市场，行业领先的软件公司 1health.io Inc (1health) 已与 Apollo Health Group 合作。 1health 帮助诊断实验室在临床和直接面向消费者的市场中快速、安全地扩展测试。

2022 年 11 月 29 日，佩奇大学 (UP) 与华大基因决定在匈牙利开设联合实验室。 这是大学与华大基因母公司华大集团之间的合作协议中规定的。

高成本预计会阻碍市场增长。

实验设备需要定期维护，成本高，是阻碍市场拓展的因素之一。

COVID-19 影响分析

COVID-19 也对市场产生了负面影响。 例如，在世卫组织将 COVID-19 指定为大流行病后，全球封锁和社会疏远对 DNA 检测市场产生了负面影响。 这是因为遗传咨询师通常无法与患者一对一会面，医生通常无法提供咨询服务，实验室也无法提供必要的检测。 遗传咨询师不被视为医疗服务中心等组织的卫生专业人员。 因此，他们在封锁期间不会免除医疗。 此外，诊所限制了现场遗传咨询以帮助控制疾病。

但是，提供基因检测的公司（例如 GeneDx）会根据临床医生的要求提供基因检测选项。 正如医院和其他医疗机构正在使用远程医疗提供遗传咨询一样，诊所也开始这样做。 此外，由于其重要性，父母测试仍然是影响最小的 DNA 测试方法。

因此，COVID-19 对基因检测市场产生了重大影响。 然而，全球对基因检测的需求现在已经接近疫情前的水平，而且这种需求预计还会继续增长。

内容

第1章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第4章市场动态

  • 市场影响因素
    • 司机
      • 新测试的开发和技术突破
      • 直接面向消费者的 DNA 检测需求不断扩大
    • 约束因素
      • 高成本预计会阻碍市场增长。
    • 机会
    • 影响分析

第5章行业分析

  • 波特的五力分析
  • 供应链分析
  • 定价分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按产品类型

  • 乐器
  • 试剂
  • 软件与服务

第8章技术

  • 聚合□链反应
  • 原位杂交
  • 音序器技术
  • 质谱
  • 其他

第 9 章按应用

  • 肿瘤学
  • 传染病检测
  • 肌源性疾病诊断
  • 临床诊断确认
  • 产前诊断
  • 植入前诊断
  • 其他

第 10 章最终用户

  • 护理点
  • 诊断中心
  • 自测/OTC

第11章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第12章竞争格局

  • 主要发展和战略
  • 公司股票分析
  • 产品基准
  • 值得关注的主要公司名单

第13章公司简介

  • Natera, Inc.
    • 公司简介
    • 产品组合和说明
    • 主要亮点
    • 财务摘要
  • Roche Diagnostics
  • Abbott Laboratories
  • Cephide Inc
  • Gen-probe Inc
  • Illumina, Inc.
  • Thermo Fisher Scientific
  • Bio-Rad Laboratories
  • Hologic Inc
  • Siemens Healthier.

第14章 全球 DNA 检测市场-DataM

简介目录
Product Code: DMCD1818

Market Overview

The global DNA testing market size was valued at US$ XX million in 2023 and is estimated to reach US$ XX million by 2030, growing at a CAGR of 7.4% during the forecast period (2023-2030).

A DNA test, often known as genetic testing, is a medical examination that can spot changes in human genes, chromosomes, or proteins. These mutations can reveal if a person has a genetic disorder or not. DNA tests can also determine a person's risk of contracting a certain illness or passing along a genetic problem. Testing for DNA is optional. Whether to be tested is complex and personal because there are advantages to testing and drawbacks and risks. A geneticist or genetic counselor can assist by outlining the advantages and disadvantages of the test and by going over its social and emotional implications.

Market Dynamics

The major factors driving the global DNA testing market are the development of new tests and technological breakthroughs, demand for direct-to-consumer DNA testing is expanding. and the growing frequency of genetic and chronic diseases is the primary driver propelling the global market for genetic testing.

The development of new tests and technological breakthroughs is expected to drive the market's growth.

The current acceleration of technical development has opened up a wide range of opportunities for market growth. The increase helps the market for specialist testing kits for specialized treatment sectors and the rapid market expansion of chronic diseases. Governments in several countries have successfully accelerated the global acceptance of genetic testing by putting more emphasis on regulating it and increasing public awareness of it. A high entry barrier for new entrants has been created by the increased R&D funding and the large market presence of major enterprises. Innovation in product design, higher quality standards, and strong distribution alliances are all necessary to keep a competitive edge in the market.

For instance, in July 2022, to bring Apollo's specialized high performing NGS tests, such as hereditary cancer genetic screenings (GCC) and pharmacogenetics screenings (PGx), to the wider clinical market, 1health.io Inc. ("1health"), an industry-leading software company, partners with Apollo Health Group. 1health empowers diagnostic laboratories to expand their testing in both the clinical and the direct-to-consumer markets rapidly and securely.

On November 29, 2022, The University of Pecs (UP) and BGI Genomics decided to open a collaborative lab in Hungary. This is a provision of the cooperation agreement between the University and BGI Group, the parent organization of BGI Genomics.

Expensive cost is expected to hamper the market's growth.

The laboratory equipment needs routine maintenance, which costs a lot of money and is one of the factors limiting market expansion.

COVID-19 Impact Analysis

COVID-19 has also had a detrimental impact on the market. For instance, the global use of lockdowns to follow social segregation to contain COVID-19 after the WHO labeled it a pandemic has negatively impacted the DNA testing market. Genetic counselors are generally unable to meet with patients one-on-one, doctors are often unavailable for counseling, and laboratories cannot do the necessary tests, which is the cause of this. Genetic counselors are not considered healthcare professionals by organizations like the Centres for Medical Services. Therefore they are not exempt from practicing during a lockdown. Additionally, clinics limited in-person genetic counseling to aid in the disease's containment.

However, companies that offer genetic testing, like GeneDx, offer a choice where they give the genetic tests as required by the clinician. Similar to how hospitals and other healthcare facilities use telehealth to offer genetic counseling, clinics are starting to do the same. Additionally, because of its importance, parental testing continues to be the least impacted method of DNA testing.

Consequently, COVID-19 has greatly impacted the market for genetic testing. However, the demand for genetic tests has currently approached pre-pandemic levels globally, and it is anticipated that this need will continue to increase.

Segment Analysis

The oncology segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The application segment is the highest market holder in the global DNA Testing market. Genetic testing uses medical tests to check for specific gene variants (changes). Several different genetic tests are being used today, and more are being created. There are numerous applications for genetic testing, but this article will concentrate on how it is used to find gene mutations connected to cancer. Predictive genetic testing is used to look for inherited gene alterations that may increase a person's chance of developing particular types of cancer. People with a history of cancer or a particular pattern of cancer in their family may benefit from genetic counseling and testing.

During the projected period, the primary drivers of the cancer segment are the rising incidence of cancers worldwide and the rising public awareness of preventive diagnostics and individualized medication. The American Cancer Society predicted that in 2021 there would be roughly 1,898,160 new cancer cases and 608,570 cancer deaths in the country. The International Agency for Research on Cancer also predicted that by 2040, there would be 30.2 million additional cases of cancer (IARC). Consequently, it is anticipated that an increase in cancer incidence will considerably contribute to the segment's growth.

Genetic tests help determine whether cancer runs in the family and the risk factors for cancer development in the future for people with a family history of the disease. Additionally, genetic testing is done on individuals who do not react to chemotherapy to determine if tumors resistant to treatment have acquired mutations.

Geographical Analysis

Asia Pacific holds the largest market share in the global DNA testing market.

Asia Pacific dominates the global DNA testing market primarily due to its large population, excellent medical infrastructure, and high-income levels. Due to the rising frequency of chronic and genetic conditions in the region and the rising demand for individualized genetic testing services, Asia Pacific now dominates the global market for genetic testing. The market expansion in the Asia Pacific is predicted to be driven by the rising number of product approvals by governments and subsequent launches, as well as the high concentration of key players engaged in research activities to innovate novel genetic testing products.

In August 2022, the debut of GENEe- TO The GENE, THE CORRECT WAY, a cutting-edge idea for providing Genetic Counselling services to patients, has been eagerly anticipated by Redcliffe Labs. Additionally, customers can use the recently opened, cutting-edge Genetic Lab in India, the country's first of its type. Redcliffe Labs hopes to provide a complete solution ranging from routine pathology at the basic level to clinical and high-end research genomics with the opening of a specialist Genetics Lab.

In May 2020, A new step of their collaboration with Illumina was announced by the Chinese company Burning Rock, a leader in next-generation sequencing (NGS) oncology diagnosis. In accordance with the new contract, Burning Rock will be the first genetic testing business in China to create in vitro diagnostic (IVD) tests using tissue samples and circulating tumor DNA (ctDNA) on Illumina's NextSeq 550Dx Sequencing System. The cooperation expands on a 2015 partnership that enabled the use of the MiSeq Dx Sequencing System for several NGS-based cancer therapy selection solutions.

Competitive Landscape

The DNA testing market is moderately competitive with local and global companies' presence. Natera, Inc, Roche Diagnostics, Abbott Laboratories, Cephide Inc, Gen-probe Inc, Illumina, Inc., Thermo Fisher Scientific, Bio-Rad Laboratories, Hologic Inc, Siemens Healthier and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in October 2022, Medline announced its multi-year vendor partnership with Hoag Memorial Hospital Presbyterian health system to provide essential medical supplies portfolio to the acute and non-acute care network.

Natera, Inc.

Overview: Cell-free DNA (cfDNA) testing pioneer Natera is committed to oncology, women's health, and organ health. In order to safeguard health and enable earlier and more precise actions that result in longer, healthier lives, the goal is to integrate customized genetic testing and diagnostics into the accepted standard of care.

Product Portfolio:

Panorama: Panorama is a blood-based genetic, prenatal screening test of the pregnant person that screens for common chromosomal conditions that affect a baby's health. Panorama uses SNP-based technology to deliver highly accurate results and unique insights for both singleton and twin pregnancies.

The global DNA testing market report would provide access to approx.: 45+market data table, 40+figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The development of new tests and technological breakthroughs
      • 4.1.1.2. Demand for direct-to-consumer DNA testing is expanding.
    • 4.1.2. Restraints:
      • 4.1.2.1. Expensive cost is expected to hamper the market's growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis
  • 5.4 Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Instruments
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Reagents
  • 7.4. Software & Services

8. By Technology

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 8.1.2. Market Attractiveness Index, By Technology
  • 8.2. PCR
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. In situ hybridization
  • 8.4. Sequencing Technology
  • 8.5. Mass Spectrometry
  • 8.6. Others

9. By Applications

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Applications
    • 9.1.2. Market Attractiveness Index, By Applications
  • 9.2. Oncology
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Infectious disease testing
  • 9.4. Myogenic disorder diagnosis
  • 9.5. Clinical diagnosis confirmation
  • 9.6. Prenatal diagnosis
  • 9.7. Pre-implantation diagnosis
  • 9.8. Others

10. By End-User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.1.2. Market Attractiveness Index, By End-User
  • 10.2. Point of Care
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Diagnostic Centers
  • 10.4. Self Testing/OTC

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size AnalysisUS$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Applications
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Applications
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), ByApplication
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.8.1. Germany
      • 11.3.8.2. U.K.
      • 11.3.8.3. France
      • 11.3.8.4. Italy
      • 11.3.8.5. Spain
      • 11.3.8.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Applications
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.8.1. Brazil
      • 11.4.8.2. Argentina
      • 11.4.8.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Applications
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.8.1. China
      • 11.5.8.2. India
      • 11.5.8.3. Japan
      • 11.5.8.4. Australia
      • 11.5.8.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Applications
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Products Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. Natera, Inc
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Roche Diagnostics
  • 13.3. Abbott Laboratories
  • 13.4. Cephide Inc
  • 13.5. Gen-probe Inc
  • 13.6. Illumina, Inc.
  • 13.7. Thermo Fisher Scientific
  • 13.8. Bio-Rad Laboratories
  • 13.9. Hologic Inc
  • 13.10. Siemens Healthier.

LIST NOT EXHAUSTIVE

14. Global DNA Testing Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Application
  • 14.3. Contact Us